OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in oncology
2021;11 665634.

Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors.

Manon Douyère, Pascal Chastagner, Cédric Boura
Author Information
  1. Manon Douyère: Université de Lorraine, CNRS, CRAN, Nancy, France.
  2. Pascal Chastagner: Université de Lorraine, CNRS, CRAN, Nancy, France.
  3. Cédric Boura: Université de Lorraine, CNRS, CRAN, Nancy, France.
PMID: 34277411 DOI: 10.3389/fonc.2021.665634

Abstract

Neuropilins are transmembrane glycoproteins that play important roles in cardiovascular and neuronal development, as well as in immunological system regulations. NRP1 functions as a co-receptor, binding numerous ligands, such as SEMA 3 or VEGF and, by doing so, reinforcing their signaling pathways and can also interface with the cytoplasmic protein synectin. NRP1 is expressed in many cancers, such as brain cancers, and is associated with poor prognosis. The challenge today for patients with pediatric brain tumors is to improve their survival rate while minimizing the toxicity of current treatments. The aim of this review is to highlight the involvement of NRP1 in pediatric brain cancers, focusing essentially on the roles of NRP1 in cancer stem cells and in the regulation of the immune system. For this purpose, recent literature and tumor databases were analyzed to show correlations between NRP1 and CD15 (a stem cancer cells marker), and between NRP1 and PDL1, for various pediatric brain tumors, such as high- and low-grade gliomas, medulloblastomas, and ependymomas. Finally, this review suggests a relevant role for NRP1 in pediatric brain tumors progression and identifies it as a potential diagnostic or therapeutic target to improve survival and life quality of these young patients.

Keywords

cancer stem cells glioma immune system medulloblastoma neuropilins pediatric brain tumor

References

  1. J Neurooncol. 2013 Nov;115(2):161-8 [PMID: 24026530]
  2. Neuro Oncol. 2016 Feb;18(2):173-83 [PMID: 26627848]
  3. Int J Exp Pathol. 2012 Apr;93(2):81-103 [PMID: 22414290]
  4. Neuro Oncol. 2010 Dec;12(12):1257-68 [PMID: 20861086]
  5. Pediatr Endocrinol Rev. 2010 Sep;8(1):6-17 [PMID: 21037539]
  6. Cell. 2008 May 16;133(4):704-15 [PMID: 18485877]
  7. J Med Chem. 2018 May 10;61(9):4135-4154 [PMID: 29648813]
  8. Biochem J. 2008 Apr 15;411(2):211-26 [PMID: 18363553]
  9. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2040-5 [PMID: 21245328]
  10. Nat Commun. 2019 Jul 26;10(1):3345 [PMID: 31350404]
  11. J Immunol. 2018 Aug 1;201(3):897-907 [PMID: 29898965]
  12. Cell. 2013 Feb 28;152(5):1065-76 [PMID: 23452854]
  13. J Clin Oncol. 2005 Aug 20;23(24):5511-9 [PMID: 16110011]
  14. Lancet. 2016 Oct 29;388(10056):2153-2163 [PMID: 27613521]
  15. Acta Neuropathol. 2016 Jun;131(6):821-31 [PMID: 27040285]
  16. Oncogene. 2007 Aug 16;26(38):5577-86 [PMID: 17369861]
  17. Sci Rep. 2015 Jul 09;5:11789 [PMID: 26156437]
  18. Int J Oncol. 2018 Jul;53(1):159-166 [PMID: 29750423]
  19. Clin Cancer Res. 2009 Nov 15;15(22):6763-70 [PMID: 19887479]
  20. Front Oncol. 2015 Jun 03;5:125 [PMID: 26090340]
  21. Int J Cancer. 2018 Aug 1;143(3):635-644 [PMID: 29457830]
  22. Clin Cancer Res. 2010 Jul 1;16(13):3368-77 [PMID: 20570930]
  23. Nature. 2013 Sep 12;501(7466):252-6 [PMID: 23913274]
  24. Dev Biol. 1987 Jul;122(1):90-100 [PMID: 3297854]
  25. J Immunol. 2006 Aug 1;177(3):1460-9 [PMID: 16849452]
  26. Cell. 1997 Aug 22;90(4):753-62 [PMID: 9288754]
  27. Oncogene. 2018 Aug;37(34):4711-4722 [PMID: 29755126]
  28. Front Immunol. 2017 Oct 10;8:1228 [PMID: 29067024]
  29. Oncotarget. 2016 Mar 1;7(9):9801-14 [PMID: 26755653]
  30. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [PMID: 12629218]
  31. Lancet Oncol. 2020 Feb;21(2):271-282 [PMID: 31838007]
  32. Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5545-50 [PMID: 17369353]
  33. J Leukoc Biol. 2016 Dec;100(6):1323-1334 [PMID: 27406993]
  34. Oncotarget. 2018 Feb 16;9(20):15312-15325 [PMID: 29632646]
  35. Microcirculation. 2014 May;21(4):315-23 [PMID: 24521511]
  36. Nature. 2007 Jan 4;445(7123):111-5 [PMID: 17122771]
  37. Br J Cancer. 2012 Feb 14;106(4):678-84 [PMID: 22333707]
  38. J Leukoc Biol. 2008 Jul;84(1):302-10 [PMID: 18436584]
  39. Oncogene. 2016 Aug 18;35(33):4379-87 [PMID: 26804163]
  40. Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2716-36 [PMID: 25192704]
  41. J Biol Chem. 2017 Jun 16;292(24):10295-10305 [PMID: 28468826]
  42. Cancer Immunol Immunother. 2014 Feb;63(2):81-99 [PMID: 24263240]
  43. Oncogene. 2017 Feb 2;36(5):606-617 [PMID: 27775079]
  44. Sci Rep. 2017 Sep 8;7(1):10941 [PMID: 28887477]
  45. PLoS One. 2017 Sep 22;12(9):e0185065 [PMID: 28938007]
  46. EMBO Mol Med. 2013 Apr;5(4):488-508 [PMID: 23436775]
  47. Cancer Cell. 2019 Sep 16;36(3):302-318.e7 [PMID: 31474569]
  48. Biochem Soc Trans. 2014 Dec;42(6):1623-8 [PMID: 25399580]
  49. J Child Neurol. 2008 Oct;23(10):1149-59 [PMID: 18952581]
  50. J Clin Oncol. 2010 Mar 10;28(8):1337-44 [PMID: 20142589]
  51. PLoS One. 2018 Dec 18;13(12):e0209193 [PMID: 30562369]
  52. Semin Cancer Biol. 2020 Feb;60:166-180 [PMID: 31369817]
  53. Nature. 2004 Nov 18;432(7015):396-401 [PMID: 15549107]
  54. J Clin Oncol. 2017 Jul 20;35(21):2370-2377 [PMID: 28640698]
  55. Neuron. 2007 Dec 6;56(5):807-22 [PMID: 18054858]
  56. Expert Opin Ther Targets. 2015 Feb;19(2):147-61 [PMID: 25351619]
  57. Genes Dev. 2008 Feb 15;22(4):436-48 [PMID: 18281460]
  58. Oncoimmunology. 2018 May 24;7(9):e1462430 [PMID: 30228931]
  59. Nat Genet. 2012 Jan 29;44(3):251-3 [PMID: 22286216]
  60. Cancer Cell. 2015 May 11;27(5):728-43 [PMID: 25965575]
  61. Cancer Cell. 2013 Dec 9;24(6):695-709 [PMID: 24332039]
  62. Mol Carcinog. 2006 Nov;45(11):871-80 [PMID: 16847823]
  63. Cell Physiol Biochem. 2017;44(3):1251-1262 [PMID: 29179185]
  64. Neuron. 1997 Sep;19(3):547-59 [PMID: 9331348]
  65. Oncotarget. 2016 Sep 6;7(36):57851-57865 [PMID: 27506939]
  66. Immunity. 2008 Mar;28(3):402-13 [PMID: 18328743]
  67. PLoS One. 2016 Feb 22;11(2):e0147358 [PMID: 26900851]
  68. Cancer Res. 2005 Apr 15;65(8):3025-9 [PMID: 15833827]
  69. Int J Mol Sci. 2018 Dec 13;19(12): [PMID: 30551640]
  70. Oncogene. 2004 Sep 20;23(43):7267-73 [PMID: 15378086]
  71. Elife. 2015 Sep 15;4: [PMID: 26371509]
  72. Eur J Immunol. 2004 Mar;34(3):623-630 [PMID: 14991591]
  73. Semin Cancer Biol. 2015 Apr;31:16-27 [PMID: 24956577]
  74. PLoS One. 2014 Jul 07;9(7):e101931 [PMID: 24999732]
  75. J Immunol. 2010 Nov 15;185(10):6373-83 [PMID: 20937848]
  76. Hum Immunol. 2009 Apr;70(4):211-7 [PMID: 19480842]
  77. J Intern Med. 2016 Jun;279(6):541-62 [PMID: 26748421]
  78. Cancer Res. 2018 Oct 1;78(19):5600-5617 [PMID: 30111533]
  79. Biochem J. 2010 Mar 15;427(1):29-40 [PMID: 20102335]
  80. Tumour Biol. 2016 Oct;37(10):13777-13788 [PMID: 27481513]
  81. J Neurooncol. 2012 Mar;107(1):29-36 [PMID: 21979892]
  82. J Clin Oncol. 2015 Mar 20;33(9):1015-22 [PMID: 25667294]
  83. J Biol Chem. 2008 Sep 12;283(37):25110-25114 [PMID: 18628209]
  84. Oncogene. 2020 Nov;39(48):7114-7126 [PMID: 33005016]
  85. Cancer. 2019 Jun 1;125(11):1867-1876 [PMID: 30768777]
  86. J Biol Chem. 2007 Aug 17;282(33):24049-56 [PMID: 17575273]
  87. F1000Res. 2017 Apr 13;6:490 [PMID: 28713553]
  88. Nature. 2014 Feb 27;506(7489):451-5 [PMID: 24553141]
  89. Curr Probl Pediatr Adolesc Health Care. 2016 Jul;46(7):242-250 [PMID: 27230809]
  90. Development. 2015 Dec 15;142(24):4363-73 [PMID: 26586223]
  91. Cancer Cell. 2014 Jul 14;26(1):33-47 [PMID: 24954133]
  92. Carcinogenesis. 2011 Apr;32(4):613-21 [PMID: 21186301]
  93. Sci Signal. 2018 May 01;11(528): [PMID: 29717062]
  94. Anticancer Agents Med Chem. 2016;16(1):101-7 [PMID: 26299661]
  95. Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006502 [PMID: 22762016]
  96. Acta Neuropathol. 2016 Jan;131(1):137-46 [PMID: 26482474]
  97. Mol Cancer Ther. 2006 May;5(5):1099-107 [PMID: 16731741]
  98. Cancer Res. 2007 Nov 1;67(21):10309-16 [PMID: 17974973]
  99. Front Cell Dev Biol. 2020 Jul 17;8:662 [PMID: 32766254]
  100. Cancer Cell. 2009 Feb 3;15(2):135-47 [PMID: 19185848]
  101. Pancreas. 2014 Jul;43(5):744-9 [PMID: 24632553]
  102. Front Oncol. 2013 Feb 28;3:28 [PMID: 23450706]
  103. Development. 1995 Dec;121(12):4309-18 [PMID: 8575331]
  104. Development. 1999 Nov;126(21):4895-902 [PMID: 10518505]
  105. Cancer Res. 2006 Oct 1;66(19):9339-44 [PMID: 16990346]
  106. Cell Rep. 2014 Dec 11;9(5):1812-1826 [PMID: 25464848]
  107. J Clin Oncol. 2017 Sep 1;35(25):2934-2941 [PMID: 28727518]
  108. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [PMID: 14645703]
  109. Acta Neuropathol. 2012 Sep;124(3):439-47 [PMID: 22661320]
  110. Adv Exp Med Biol. 2002;515:33-48 [PMID: 12613541]
  111. Nat Rev Clin Oncol. 2018 Nov;15(11):659-660 [PMID: 30030473]
  112. J Pathol. 2020 Jul;251(3):249-261 [PMID: 32391583]
  113. Curr Opin Hematol. 2016 May;23(3):260-7 [PMID: 26849476]
  114. J Neurooncol. 2016 May;128(1):29-34 [PMID: 26951556]
  115. Nat Immunol. 2002 May;3(5):477-82 [PMID: 11953749]
  116. Nat Immunol. 2010 Jul;11(7):594-600 [PMID: 20512151]
  117. J Exp Med. 2012 Mar 12;209(3):507-20 [PMID: 22393126]
  118. J Biol Chem. 2002 May 17;277(20):18069-76 [PMID: 11886873]
  119. Nature. 2012 Jan 29;482(7384):226-31 [PMID: 22286061]
  120. Tohoku J Exp Med. 2016;238(2):85-91 [PMID: 26753562]
  121. Int J Mol Sci. 2019 Feb 01;20(3): [PMID: 30717262]
  122. J Biol Chem. 2005 Apr 8;280(14):13457-64 [PMID: 15695515]
  123. Oncoscience. 2015 Mar 02;2(4):334-48 [PMID: 26097868]
  124. PLoS One. 2014 Jul 28;9(7):e103405 [PMID: 25068647]
  125. Cancer Res. 2012 Aug 15;72(16):4047-59 [PMID: 22738912]
  126. Glia. 2002 Sep;39(3):193-206 [PMID: 12203386]
  127. Anticancer Res. 2004 Mar-Apr;24(2B):547-52 [PMID: 15160992]
  128. PLoS Biol. 2009 Jan 27;7(1):e25 [PMID: 19175293]
  129. Acta Neuropathol. 2016 Jun;131(6):803-20 [PMID: 27157931]
  130. J Neurosurg Pediatr. 2019 Mar 1;23(3):261-273 [PMID: 30835699]
  131. Cell. 2017 Jun 1;169(6):1130-1141.e11 [PMID: 28552348]
  132. J Child Neurol. 2016 Oct;31(12):1341-53 [PMID: 26336203]
  133. Invest New Drugs. 2014 Aug;32(4):653-60 [PMID: 24604265]
  134. Cancer Lett. 2016 Apr 1;373(1):1-11 [PMID: 26805761]
  135. J Exp Med. 2012 Oct 22;209(11):2001-16 [PMID: 23045606]
  136. Oncotarget. 2015 May 10;6(13):10697-711 [PMID: 25986923]
  137. Cancer Res. 2018 Feb 1;78(3):685-694 [PMID: 29097606]
  138. Curr Opin Oncol. 2017 Nov;29(6):443-447 [PMID: 28885433]
  139. Int J Mol Sci. 2019 Jan 23;20(3): [PMID: 30678134]
  140. Cancer. 2002 Nov 15;95(10):2196-201 [PMID: 12412174]
  141. PLoS One. 2011 Jan 28;6(1):e16375 [PMID: 21297991]
  142. Cancer Lett. 2013 Sep 10;338(1):23-31 [PMID: 22796365]
  143. Biochemistry (Mosc). 2007 Nov;72(11):1194-8 [PMID: 18205601]
  144. Cell. 1998 Mar 20;92(6):735-45 [PMID: 9529250]
  145. Signal Transduct Target Ther. 2020 Feb 7;5(1):8 [PMID: 32296030]
Journal Article Review
Article has an altmetric score of 8

Word Cloud

Created with Highcharts 10.0.0NRP1brainpediatricsystemcancerstumorscancerstemcellsrolespatientsimprovesurvivalreviewimmunetumorNeuropilinstransmembraneglycoproteinsplayimportantcardiovascularneuronaldevelopmentwellimmunologicalregulationsfunctionsco-receptorbindingnumerousligandsSEMA3VEGFreinforcingsignalingpathwayscanalsointerfacecytoplasmicproteinsynectinexpressedmanyassociatedpoorprognosischallengetodayrateminimizingtoxicitycurrenttreatmentsaimhighlightinvolvementfocusingessentiallyregulationpurposerecentliteraturedatabasesanalyzedshowcorrelationsCD15markerPDL1varioushigh-low-gradegliomasmedulloblastomasependymomasFinallysuggestsrelevantroleprogressionidentifiespotentialdiagnostictherapeutictargetlifequalityyoungNeuropilin-1:KeyProteinConsiderProgressionPediatricBrainTumorsgliomamedulloblastomaneuropilins

Similar Articles

Cited By